search
Back to results

Progesterone and Cervical Pessary in Twins (PRECEPET)

Primary Purpose

Preterm Birth, Twin Pregnancy With Antenatal Problem

Status
Unknown status
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Arabin Pessary
Vaginal Progesterone
Arabin Pessary and Progesterone
Sponsored by
Mario Henrique Burlacchini de Carvalho
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Preterm Birth focused on measuring twin short cervix pessary progesterone preterm birth

Eligibility Criteria

16 Years - 50 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Twin pregnancy ( dichorionic or monochorionic diamniotic)
  • Both fetuses alive
  • Asymptomatic short cervix according to gestational age ( measurement less or equal 30 mm between 16 weeks + 0 day and 22 weeks + 0 day, less or equal 25 mm between 22 weeks + 1 day and 24 weeks + 0 day and less or equal 20 mm between 24 weeks + 1 day and 27 weeks + 6 days)
  • Gestational age between 16 to 27weeks and 6 days
  • Intact membranes
  • Informed consent

Exclusion Criteria:

  • Monoamniotic twins
  • Twin Twin transfusion syndrome
  • Rupture membranes
  • Major malformation or chromosomal abnormality at least one fetus
  • Women with Cervical cerclage in the current pregnancy
  • Ballooning of membranes outside the cervix into the vagina
  • Placenta previa
  • Treatment with progesterone before randomization
  • Allergy of the excipientes of the micronized progesterone
  • Labor
  • Severe hepatic disfunction, porphyria, otosclerosis, severe depression
  • Use of drugs that interfere the effects of progesterone

Sites / Locations

  • Hospital das Clinicas da FMUSPRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

No Intervention

Arm Label

Progesterone

Arabin Pessary and Progesterone

Arabin Pessary

No intervention

Arm Description

400 mg micronized vaginal progesterone daily from randomization to 36 weeks

Arabin Pessary and Natural Micronized Progesterone 400 mg micronized vaginal progesterone daily from randomization to 36 weeks The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone.

The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.

Expectant management

Outcomes

Primary Outcome Measures

Preterm birth
Rate of preterm birth before 34 weeks gestation

Secondary Outcome Measures

Neonatal Complications Rate
Includes necrotizing enterocolitis, intraventricular hemorrhage (grade 3 or higher), respiratory distress syndrome, retinopathy, sepsis, use of mechanical ventilation, time of hospitalization, and neonatal death.
Months from Randomization to delivery interval
Randomization may begin at 16 weeks, and most patient will be delivered between 36 and 38 weeks gestation.

Full Information

First Posted
February 5, 2017
Last Updated
March 13, 2017
Sponsor
Mario Henrique Burlacchini de Carvalho
search

1. Study Identification

Unique Protocol Identification Number
NCT03058536
Brief Title
Progesterone and Cervical Pessary in Twins
Acronym
PRECEPET
Official Title
Progesterone and Cervical Pessary in Twins : A Prospective and Randomized Study to Prevent Preterm Birth (PRECEPT)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 21, 2017 (Actual)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
March 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mario Henrique Burlacchini de Carvalho

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this randomized control trial is to determine wheter cervical pessary plus vaginal progesterone (400mg) reduce preterm birth less than 34 weeks of gestacion and improve perinatal outcome, among women presenting asyntomatic short cervix, in twin pregnancy.
Detailed Description
The frequency of twin pregnancies has increased significantly, especially because of the assisted reproduction and advanced maternal age at conception. The twin pregnancies are responsible for 25 % of all preterm birth. Consequently, twin pregnancies are more associated with perinatal mortality and morbidity when compared to single pregnancies. Additionally, the short cervix (< 25 mm) in singleton and twin pregnancies are associated with significantly increased preterm birth. Randomized controlled trials in singleton pregnancies reported that profilatic cervical cerclage and vaginal progesterone reduce significantly the rate of early preterm birth. In twin pregnancies, vaginal progesterone and profilatic cerclage have been shown to be ineffective in prevention of preterm birth. However, two individual pacient data meta-analyses reported in a subgroup of women with twin pregancies and short cervix, that vaginal progesterone reduce significantly adverse neonatal outcomes. Nowadays, the effet of cervical pessary is contraditory, mainly in women with short cervix. This is a randomized prospective trial at São Paulo University Medical School. This trial will involve 312 women with twins pregnancies and short cervix between 16 and 27 weeks and 6 days of gestacional age. Women with twin pregnancy and short cervix ( defined according to the gestacional age ) will be assigned randomly to daily vaginal progesterone (400mg) combined with insertion of cervical pessary, isolated use of daily vaginal progesterone (400mg) isolated insertion of cervical pessary or expectant management (no intervention). The primary outcome is to compare the rate of spontaneous delivery < 34 weeks of gestacion between groups.The secondary outcome is to compare the neonatal adverse outcome between the groups. The aim of this study is to test the hypothesis that the insertion of a cervical pessary combined with vaginal progesterone, in twin pregnancies with short cervix would reduce the spontaneus preterm birth < 34 weeks' gestation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Birth, Twin Pregnancy With Antenatal Problem
Keywords
twin short cervix pessary progesterone preterm birth

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
312 twin pregnant women with short cervix between 16 and 27 weeks and 6 days of gestacional age will be randomized in four groups: daily 400mg vaginal progesterone combined with insertion of cervical pessary; isolated use of daily 400mg vaginal progesterone, isolated insertion of cervical pessary or expectant management (no intervention).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
312 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Progesterone
Arm Type
Active Comparator
Arm Description
400 mg micronized vaginal progesterone daily from randomization to 36 weeks
Arm Title
Arabin Pessary and Progesterone
Arm Type
Active Comparator
Arm Description
Arabin Pessary and Natural Micronized Progesterone 400 mg micronized vaginal progesterone daily from randomization to 36 weeks The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone.
Arm Title
Arabin Pessary
Arm Type
Active Comparator
Arm Description
The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
Arm Title
No intervention
Arm Type
No Intervention
Arm Description
Expectant management
Intervention Type
Device
Intervention Name(s)
Arabin Pessary
Intervention Description
The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
Intervention Type
Drug
Intervention Name(s)
Vaginal Progesterone
Other Intervention Name(s)
Utrogestan
Intervention Description
Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
Intervention Type
Other
Intervention Name(s)
Arabin Pessary and Progesterone
Intervention Description
Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
Primary Outcome Measure Information:
Title
Preterm birth
Description
Rate of preterm birth before 34 weeks gestation
Time Frame
5 months
Secondary Outcome Measure Information:
Title
Neonatal Complications Rate
Description
Includes necrotizing enterocolitis, intraventricular hemorrhage (grade 3 or higher), respiratory distress syndrome, retinopathy, sepsis, use of mechanical ventilation, time of hospitalization, and neonatal death.
Time Frame
between birth and 28 days of age
Title
Months from Randomization to delivery interval
Description
Randomization may begin at 16 weeks, and most patient will be delivered between 36 and 38 weeks gestation.
Time Frame
6 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
pregnant women
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Twin pregnancy ( dichorionic or monochorionic diamniotic) Both fetuses alive Asymptomatic short cervix according to gestational age ( measurement less or equal 30 mm between 16 weeks + 0 day and 22 weeks + 0 day, less or equal 25 mm between 22 weeks + 1 day and 24 weeks + 0 day and less or equal 20 mm between 24 weeks + 1 day and 27 weeks + 6 days) Gestational age between 16 to 27weeks and 6 days Intact membranes Informed consent Exclusion Criteria: Monoamniotic twins Twin Twin transfusion syndrome Rupture membranes Major malformation or chromosomal abnormality at least one fetus Women with Cervical cerclage in the current pregnancy Ballooning of membranes outside the cervix into the vagina Placenta previa Treatment with progesterone before randomization Allergy of the excipientes of the micronized progesterone Labor Severe hepatic disfunction, porphyria, otosclerosis, severe depression Use of drugs that interfere the effects of progesterone
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mario Henrique Burlacchini de Carvalho, PhD
Phone
+55 11 26616209
Ext
3183
Email
mario.burlacchini@hc.fm.usp.br
First Name & Middle Initial & Last Name or Official Title & Degree
Carolina Fiuza Branco
Phone
+55 11 986974207
Email
carolfiuzabranco@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mario Henrique Burlacchini de Carvalho, PhD
Organizational Affiliation
Hospital das Clínicas Universidade de São Paulo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital das Clinicas da FMUSP
City
Sao Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Henrique Burlacchini de Carvalho, PhD
Phone
551126616209
Email
marioburlacchini@uol.com.br

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26333191
Citation
Kindinger LM, Poon LC, Cacciatore S, MacIntyre DA, Fox NS, Schuit E, Mol BW, Liem S, Lim AC, Serra V, Perales A, Hermans F, Darzi A, Bennett P, Nicolaides KH, Teoh TG. The effect of gestational age and cervical length measurements in the prediction of spontaneous preterm birth in twin pregnancies: an individual patient level meta-analysis. BJOG. 2016 May;123(6):877-84. doi: 10.1111/1471-0528.13575. Epub 2015 Sep 1.
Results Reference
background
PubMed Identifier
22284156
Citation
Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012 Feb;206(2):124.e1-19. doi: 10.1016/j.ajog.2011.12.003. Epub 2011 Dec 11.
Results Reference
background
PubMed Identifier
19523680
Citation
Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, Calder A, Mires G, Danielian P, Sturgiss S, MacLennan G, Tydeman G, Thornton S, Martin B, Thornton JG, Neilson JP, Norrie J. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet. 2009 Jun 13;373(9680):2034-40. doi: 10.1016/S0140-6736(09)60947-8.
Results Reference
background
PubMed Identifier
25731690
Citation
Brizot ML, Hernandez W, Liao AW, Bittar RE, Francisco RPV, Krebs VLJ, Zugaib M. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2015 Jul;213(1):82.e1-82.e9. doi: 10.1016/j.ajog.2015.02.021. Epub 2015 Feb 27.
Results Reference
background
PubMed Identifier
25145491
Citation
Schuit E, Stock S, Rode L, Rouse DJ, Lim AC, Norman JE, Nassar AH, Serra V, Combs CA, Vayssiere C, Aboulghar MM, Wood S, Cetingoz E, Briery CM, Fonseca EB, Worda K, Tabor A, Thom EA, Caritis SN, Awwad J, Usta IM, Perales A, Meseguer J, Maurel K, Garite T, Aboulghar MA, Amin YM, Ross S, Cam C, Karateke A, Morrison JC, Magann EF, Nicolaides KH, Zuithoff NP, Groenwold RH, Moons KG, Kwee A, Mol BW; Global Obstetrics Network (GONet) collaboration. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. BJOG. 2015 Jan;122(1):27-37. doi: 10.1111/1471-0528.13032. Epub 2014 Aug 22.
Results Reference
background
PubMed Identifier
21739497
Citation
Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011 Sep;38(3):272-80. doi: 10.1002/uog.9093.
Results Reference
background
PubMed Identifier
26627728
Citation
Goya M, de la Calle M, Pratcorona L, Merced C, Rodo C, Munoz B, Juan M, Serrano A, Llurba E, Higueras T, Carreras E, Cabero L; PECEP-Twins Trial Group. Cervical pessary to prevent preterm birth in women with twin gestation and sonographic short cervix: a multicenter randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol. 2016 Feb;214(2):145-152. doi: 10.1016/j.ajog.2015.11.012. Epub 2015 Nov 25.
Results Reference
background
PubMed Identifier
23924878
Citation
Liem S, Schuit E, Hegeman M, Bais J, de Boer K, Bloemenkamp K, Brons J, Duvekot H, Bijvank BN, Franssen M, Gaugler I, de Graaf I, Oudijk M, Papatsonis D, Pernet P, Porath M, Scheepers L, Sikkema M, Sporken J, Visser H, van Wijngaarden W, Woiski M, van Pampus M, Mol BW, Bekedam D. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet. 2013 Oct 19;382(9901):1341-9. doi: 10.1016/S0140-6736(13)61408-7. Epub 2013 Aug 5.
Results Reference
background
PubMed Identifier
26959202
Citation
Fox NS, Gupta S, Lam-Rachlin J, Rebarber A, Klauser CK, Saltzman DH. Cervical Pessary and Vaginal Progesterone in Twin Pregnancies With a Short Cervix. Obstet Gynecol. 2016 Apr;127(4):625-630. doi: 10.1097/AOG.0000000000001300.
Results Reference
background
PubMed Identifier
26321037
Citation
Nicolaides KH, Syngelaki A, Poon LC, de Paco Matallana C, Plasencia W, Molina FS, Picciarelli G, Tul N, Celik E, Lau TK, Conturso R. Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. Am J Obstet Gynecol. 2016 Jan;214(1):3.e1-9. doi: 10.1016/j.ajog.2015.08.051. Epub 2015 Aug 28.
Results Reference
background

Learn more about this trial

Progesterone and Cervical Pessary in Twins

We'll reach out to this number within 24 hrs